Reference
Shi Y, et al. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature. Thoracic Cancer 9: 1788-1794, No. 12, 31 Oct 2018. Available from: URL: http://doi.org/10.1111/1759-7714.12906 - China
Rights and permissions
About this article
Cite this article
Afatinib. Reactions Weekly 1735, 19 (2019). https://doi.org/10.1007/s40278-019-56635-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-56635-0